These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 22364332)

  • 1. Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis.
    Costelloe L; Jones J; Coles A
    Expert Rev Neurother; 2012 Mar; 12(3):335-41. PubMed ID: 22364332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The outlook for alemtuzumab in multiple sclerosis.
    Williams T; Coles A; Azzopardi L
    BioDrugs; 2013 Jun; 27(3):181-9. PubMed ID: 23558379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: a review.
    Aranha AA; Amer S; Reda ES; Broadley SA; Davoren PM
    Endocr Pract; 2013; 19(5):821-8. PubMed ID: 23757618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).
    Jones JL; Phuah CL; Cox AL; Thompson SA; Ban M; Shawcross J; Walton A; Sawcer SJ; Compston A; Coles AJ
    J Clin Invest; 2009 Jul; 119(7):2052-61. PubMed ID: 19546505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis.
    Azzopardi L; Thompson SA; Harding KE; Cossburn M; Robertson N; Compston A; Coles AJ; Jones JL
    J Neurol Neurosurg Psychiatry; 2014 Jul; 85(7):795-8. PubMed ID: 24368840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alemtuzumab treatment of multiple sclerosis.
    Coles AJ
    Semin Neurol; 2013 Feb; 33(1):66-73. PubMed ID: 23709214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.
    Baker D; Herrod SS; Alvarez-Gonzalez C; Giovannoni G; Schmierer K
    JAMA Neurol; 2017 Aug; 74(8):961-969. PubMed ID: 28604916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
    Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
    J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab for Multiple Sclerosis.
    Willis MD; Robertson NP
    Curr Neurol Neurosci Rep; 2016 Sep; 16(9):84. PubMed ID: 27485945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spotlight on alemtuzumab.
    Jones JL; Coles AJ
    Int MS J; 2009 Sep; 16(3):77-81. PubMed ID: 19878629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
    ; Coles AJ; Compston DA; Selmaj KW; Lake SL; Moran S; Margolin DH; Norris K; Tandon PK
    N Engl J Med; 2008 Oct; 359(17):1786-801. PubMed ID: 18946064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.
    Hill-Cawthorne GA; Button T; Tuohy O; Jones JL; May K; Somerfield J; Green A; Giovannoni G; Compston DA; Fahey MT; Coles AJ
    J Neurol Neurosurg Psychiatry; 2012 Mar; 83(3):298-304. PubMed ID: 22056965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond.
    Ruck T; Bittner S; Wiendl H; Meuth SG
    Int J Mol Sci; 2015 Jul; 16(7):16414-39. PubMed ID: 26204829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis.
    Alamo A; Condorelli RA; La Vignera S; Calogero AE
    Int J Immunopathol Pharmacol; 2019; 33():2058738419843690. PubMed ID: 30968726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating MS: getting to know the two birds in the bush.
    Laufer TM; Wu GF
    J Clin Invest; 2009 Jul; 119(7):1852-3. PubMed ID: 19603540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort.
    Cossburn M; Pace AA; Jones J; Ali R; Ingram G; Baker K; Hirst C; Zajicek J; Scolding N; Boggild M; Pickersgill T; Ben-Shlomo Y; Coles A; Robertson NP
    Neurology; 2011 Aug; 77(6):573-9. PubMed ID: 21795656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mode of action and clinical studies with alemtuzumab.
    Jones JL; Coles AJ
    Exp Neurol; 2014 Dec; 262 Pt A():37-43. PubMed ID: 24792641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Alemtuzumab: a further option for treatment of multiple sclerosis].
    Menge T; Kieseier BC; Warnke C; Aktas O; Hartung HP
    Nervenarzt; 2012 Apr; 83(4):487-501. PubMed ID: 22038387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Alemtuzumab, a monoclonal antibody against CD52: hopes and fears].
    Mori M
    Brain Nerve; 2014 Oct; 66(10):1179-89. PubMed ID: 25296872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management.
    Decallonne B; Bartholomé E; Delvaux V; D'haeseleer M; El Sankari S; Seeldrayers P; Van Wijmeersch B; Daumerie C
    Acta Neurol Belg; 2018 Jun; 118(2):153-159. PubMed ID: 29372482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.